Cite
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
MLA
Kappos, Ludwig, et al. “Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.” JAMA Neurology, vol. 78, no. 5, May 2021, pp. 558–67. EBSCOhost, https://doi.org/10.1001/jamaneurol.2021.0405.
APA
Kappos, L., Fox, R. J., Burcklen, M., Freedman, M. S., Havrdová, E. K., Hennessy, B., Hohlfeld, R., Lublin, F., Montalban, X., Pozzilli, C., Scherz, T., D’Ambrosio, D., Linscheid, P., Vaclavkova, A., Pirozek-Lawniczek, M., Kracker, H., & Sprenger, T. (2021). Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurology, 78(5), 558–567. https://doi.org/10.1001/jamaneurol.2021.0405
Chicago
Kappos, Ludwig, Robert J Fox, Michel Burcklen, Mark S Freedman, Eva K Havrdová, Brian Hennessy, Reinhard Hohlfeld, et al. 2021. “Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.” JAMA Neurology 78 (5): 558–67. doi:10.1001/jamaneurol.2021.0405.